SurModics IVD to Present at Biomarker World Congress in Philadelphia, PA
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--May. 14, 2012--
SurModics IVD Inc., a wholly owned subsidiary of SurModics, Inc.
(NASDAQ:SRDX) and a market leader for immunoassay reagents for
diagnostic tests, is pleased to announce it will present a poster
of Immunoassay Interference Reduction Technologies” at Biomarker
World Congress in Philadelphia, PA from May 21 – 23, 2012.
The poster and representatives of SurModics will present products that
mitigate non-specific binding and interferences in immunoassays. These products
provide useful tools to develop and optimize immunoassays that are
sensitive, reproducible and robust, while demonstrating the ability to
reduce assay interference across multiple applications.
To learn more about SurModics'in vitro diagnostic products,
please visit our website (www.surmodics.com),
or contact customer service at 952-500-7200 or email@example.com.
Easy online ordering is available at http://shop.surmodics.com.
SurModics is a registered trademark of SurModics, Inc.
About SurModics, Inc.
SurModics' mission is to exceed our
customers' expectations and enhance the well-being of patients by
providing the world's foremost, innovative surface modification
technologies and in vitro diagnostic chemical components. The
Company partners with the world's leading and emerging medical device,
diagnostic and life science companies to develop and commercialize
innovative products designed to improve patient diagnosis and treatment.
Core offerings include surface modification coating technologies that
impart lubricity, prohealing, and biocompatibility capabilities; and
components for in vitro diagnostic test kits and microarrays.
SurModics is headquartered in Eden Prairie, Minnesota. For more
information about the Company, visit http://www.surmodics.com.
The content of SurModics' website is not part of this release or part of
any filings the Company makes with the SEC.
Source: SurModics, Inc.
Tim Arens, 952-500-7000
Vice President Finance
and interim Chief Financial Officer